Innate immunity in HIV infection: Enhanced susceptibility to CD95-mediated natural killer cell death and turnover induced by HIV viremia

Journal of Acquired Immune Deficiency Syndromes

Volumn 46, Issue 2, 2007, Pages 151-159

  Kottilil, Shyam ^a   Jackson, Julia O ^a   Reitano, Kristin N ^a   O'Shea, Marie Angeline ^a   Roby, Gregg ^a   Lloyd, Margaret ^b   Yang, Jun ^c   Hallahan, Claire W ^a   Rehm, Catherine A ^a   Arthos, James ^a   Lempicki, Richard ^c   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Fas; FasL; Gene expression; HIV 1; Natural killer cells

Indexed keywords

ANTIRETROVIRUS AGENT; CD16 ANTIGEN; CD56 ANTIGEN; FAS ANTIGEN; KI 67 ANTIGEN; NATURAL KILLER CELL RECEPTOR NKG2D;

ARTICLE; CELL ACTIVITY; CELL DEATH; CELL TRANSFER; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; GENETIC ANALYSIS; HOST SUSCEPTIBILITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INNATE IMMUNITY; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; SERODIAGNOSIS; VIREMIA; VIRUS REPLICATION;

ANTIGENS, CD95; APOPTOSIS; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; FAS LIGAND PROTEIN; GENE EXPRESSION PROFILING; HIV INFECTIONS; HIV-1; HUMANS; KI-67 ANTIGEN; KILLER CELLS, NATURAL; PROTEIN ARRAY ANALYSIS; RECEPTORS, IGG; RECEPTORS, IMMUNOLOGIC; VIREMIA;

EID: 34748832264     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3180dc9909     Document Type: Article

References (38)

1. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187-376.
2. Moretta A, Bottino C, Vitale M, et al. Receptors for HLA class-I molecules in human natural killer cells. Annu Rev Immunol. 1996;14:619-648.
3. Lanier LL. NK cell recognition. Annu Rev Immunol. 2005;23:225-274.
4. Moretta A, Bottino C, Mingari MC, et al. What is a natural killer cell? Nat Immunol. 2002;3:6-8.
5. Lanier LL. On guard - activating NK cell receptors. Nat Immunol. 2001;2:23-27.
6. Lanier LL, Phillips JH. Inhibitory MHC class I receptors on NK cells and T cells. Immunol Today. 1996;17:86-91.
7. Mavilio D, Benjamin J, Daucher M, et al. Natural killer cells in HIV-1 infection: dichotomous effects of viremia on inhibitory and activating receptors and their functional correlates. Proc Natl Acad Sci USA. 2003;100:15011-15016.
8. Mavilio D, Lombardo G, Benjamin J, et al. Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals. Proc Natl Acad Sci USA. 2005;102:2886-2891.
9. De Maria A, Fogli M, Costa P, et al. The impaired NK cell cytolytic function in viremic HIV-1 infection is associated with a reduced surface expression of natural cytotoxicity receptors (NKp46, NKp30 and NKp44). Eur J Immunol. 2003;33:2410-2418.
10. Kottilil S, Shin K, Jackson JO, et al. Innate immune dysfunction in HIV infection: effect of HIV envelope-NK cell interactions. J Immunol. 2006;176:1107-1114.
11. Kottilil S, Chun TW, Moir S, et al. Innate immunity in human immunodeficiency virus infection: effect of viremia on natural killer cell function. J Infect Dis. 2003;187:1038-1045.
12. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116-5121.
13. Gupta N, Arthos J, Khazanie P, et al. Targeted lysis of HIV-infected cells by natural killer cells armed and triggered by a recombinant immunoglobulin fusion protein: implications for immunotherapy. Virology. 2005;332:491-497.
14. Kovacs JA, Lempicki RA, Sidorov IA, et al. Identification of dynamically distinct subpopulations of T lymphocytes that are differentially affected by HIV. J Exp Med. 2001;194:1731-1741.
15. Anthony KB, Yoder C, Metcalf JA, et al. Incomplete CD4 T-cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T-cell activation and turnover. J Acquir Immune Defic Syndr. 2003;33:125-133.
16. Kottilil S, Shin K, Planta M, et al. Expression of chemokine and inhibitory receptors on natural killer cells: effect of immune activation and HIV viremia. J Infect Dis. 2004;189:1193-1198.
17. Oliva A, Kinter AL, Vaccarezza M, et al. Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro. J Clin Invest. 1998;102:223-231.
18. Fehniger TA, Herbein G, Yu H, et al. Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection. J Immunol. 1998;161:6433-6438.
19. Alter G, Teigen N, Davis BT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood. 2005;106:3366-3369.
20. Alter G, Malenfant JM, Delabre RM, et al. Increased natural killer cell activity in viremic HIV-1 infection. J Immunol. 2004;173:5305-5311.
21. Goodier MR, Imami N, Moyle G, et al. Loss of the CD56hiCD16-NK cell subset and NK cell interferon-gamma production during antiretroviral therapy for HIV-1: partial recovery by human growth hormone. Clin Exp Immunol. 2003;134:470-476.
22. Douglas SD, Durako SJ, Tustin NB, et al. Natural killer cell enumeration and function in HIV-infected and high-risk uninfected adolescents. AIDS Res Hum Retroviruses. 2001;17:543-552.
23. - cells with low lytic activity. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;10:331-340.
24. Bonagura VR, Cunningham-Rundles SL, Schuval S. Dysfunction of natural killer cells in human immunodeficiency virus-infected children with or without Pneumocystis carinii pneumonia. J Pediatr. 1992;121:195-201.
25. Novick DM, Ochshorn M, Ghali V, et al. Natural killer cell activity and lymphocyte subsets in parenteral heroin abusers and long-term methadone maintenance patients. J Pharmacol Exp Ther. 1989;250:606-610.
26. Meier UC, Owen RE, Taylor E, et al. Shared alterations in NK cell frequency, phenotype, and function in chronic human immunodeficiency virus and hepatitis C virus infections. J Virol. 2005;79:12365-12374.
27. Jewett A, Cavalcanti M, Giorgi J, et al. Concomitant killing in vitro of both gp120-coated CD4+ peripheral T lymphocytes and natural killer cells in the antibody-dependent cellular cytotoxicity (ADCC) system. J Immunol. 1997;158:5492-5500.
28. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2002;99:7015-7020.
29. Chun TW, Justement JS, Lempicki RA, et al. Gene expression and viral production in latently infected, resting CD4+ T cells in viremic versus aviremic HIV-infected individuals. Proc Natl Acad Sci USA. 2003;100:1908-1913.
30. Kim SY, Li J, Bentsman G, et al. Microarray analysis of changes in cellular gene expression induced by productive infection of primary human astrocytes: implications for HAD. J Neuroimmunol. 2004;157:17-26.
31. Moir S, Malaspina A, Pickeral OK, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med. 2004;200:587-599.
32. Wang Z, Trillo-Pazos G, Kim SY, et al. Effects of human immunodeficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol. 2004;10(Suppl 1):25-32.
33. Gougeon ML, Ledru E, Naora H, et al. HIV, cytokines and programmed cell death. A subtle interplay. Ann N Y Acad Sci. 2000;926:30-45.
34. Wasmuth JC, Klein KH, Hackbarth F, et al. Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis. J Acquir Immune Defic Syndr. 2000;23:44-51.
35. Vigano A, Pinti M, Nasi M, et al. Markers of cell death-activation in lymphocytes of vertically HIV-infected children naive to highly active antiretroviral therapy: the role of age. J Allergy Clin Immunol. 2001;108:439-445.
36. De Boer RJ, Mohri H, Ho DD, et al. Turnover rates of B cells, T cells, and NK cells in simian immunodeficiency virus-infected and uninfected rhesus macaques. J Immunol. 2003;170:2479-2487.
37. Mohri H, Bonhoeffer S, Monard S, et al. Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science. 1998;279:1223-1227.
38. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol. 2001;22:633-640.